Reuters logo
BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA® (pembrolizumab)
March 14, 2017 / 8:49 PM / 9 months ago

BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA® (pembrolizumab)

March 14 (Reuters) - Merck & Co Inc

* Merck provides update on supplemental biologics license application (sbla) for keytruda® (pembrolizumab) in previously treated advanced microsatellite instability-high cancer

* Merck & co inc - new fda target action date is june 9, 2017

* Merck & co-submission of additional data is considered major amendment to sbla under pdufa, thus extending target action date by three months Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below